Zobrazeno 1 - 10
of 985
pro vyhledávání: '"Vincent A. Miller"'
Autor:
Apostolia Maria Tsimberidou, David S. Hong, Siqing Fu, Daniel D. Karp, Sarina Piha-Paul, Merrill S. Kies, Vinod Ravi, Vivek Subbiah, Sunil M. Patel, Shi-Ming Tu, Filip Janku, John Heymach, Amber Johnson, Carrie Cartwright, Li Zhao, Jianhua Zhang, Donald A. Berry, David J. Vining, Andrew Futreal, Vincent A. Miller, Funda Meric-Bernstam
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-9 (2021)
Abstract Precision medicine is associated with favorable outcomes in selected patients with cancer. Herein, we report an interim analysis of IMPACT2, an ongoing randomized study evaluating genomic profiling and targeted agents in metastatic cancer. P
Externí odkaz:
https://doaj.org/article/33315794ca1f4daf8eba5da8574c8e3f
Autor:
Jamie A. Kmak, Nikita Agarwal, Yuting He, Andreas M. Heilmann, Vincent A. Miller, Jeffrey S. Ross, Sumanta Kumar Pal, Siraj M. Ali, Deepak Kilari
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 456-461 (2020)
Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma.
Externí odkaz:
https://doaj.org/article/2ce5d4c419d14d088d5076eeacb1032e
Autor:
Jonathan W. Riess, Shaila Rahman, Waleed Kian, Claire Edgerly, Andreas M. Heilmann, Russell Madison, Shakti H. Ramkissoon, Shai Shlomi Klaitman, Jon H. Chung, Sally E. Trabucco, Dexter X. Jin, Brian M. Alexander, Samuel J. Klempner, Lee A. Albacker, Garrett M. Frampton, Laila C. Roisman, Vincent A. Miller, Jeffrey S. Ross, Alexa B. Schrock, Jeffrey P. Gregg, Nir Peled, Ethan S. Sokol, Siraj M. Ali
Publikováno v:
Translational Oncology, Vol 14, Iss 10, Pp 101184- (2021)
Background: The translocation t(15:19) produces the oncogenic BRD4-NUT fusion which is pathognomonic for NUT carcinoma (NC), which is a rare, but extremely aggressive solid tumor. Comprehensive genomic profiling (CGP) by hybrid-capture based next gen
Externí odkaz:
https://doaj.org/article/f78f81cbdd204e1789f4f2191a1fc032
Autor:
Cathy Zhou, Zilong Yuan, Weijie Ma, Lihong Qi, Angelique Mahavongtrakul, Ying Li, Hong Li, Jay Gong, Reggie R. Fan, Jin Li, Michael Molmen, Travis A. Clark, Dean Pavlick, Garrett M. Frampton, Brady Forcier, Elizabeth H. Moore, David K. Shelton, Matthew Cooke, Siraj M. Ali, Vincent A. Miller, Jeffrey P. Gregg, Philip J. Stephens, Tianhong Li
Publikováno v:
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-13 (2018)
Abstract Background This retrospective study was undertaken to determine if the plasma circulating tumor DNA (ctDNA) level and tumor biological features in patients with advanced solid tumors affected the detection of genomic alterations (GAs) by a p
Externí odkaz:
https://doaj.org/article/f7a6b3e50e784343a7af265214bc7dc3
Autor:
Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio, Laurie Gay, Siraj M. Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, Steven Roels, Jared White, Geoffrey A. Otto, Jeffrey S. Ross, Levi Garraway, Vincent A. Miller, Phillip J. Stephens, Garrett M. Frampton
Publikováno v:
Genome Medicine, Vol 9, Iss 1, Pp 1-14 (2017)
Abstract Background High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or
Externí odkaz:
https://doaj.org/article/fb907a4b3aaf43769173e9ac0018e2eb
Autor:
Jon H. Chung, Siraj M. Ali, Jenni Davis, Karl Robstad, Richard McNally, Laurie M. Gay, Rachel L. Erlich, Norma A. Palma, Phil J. Stephens, Vincent A. Miller, Alfonso Cutugno, Jeffrey S. Ross
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 3, Pp 628-632 (2014)
Suspected metastatic site lesions that are poorly differentiated present a diagnostic challenge when morphologic and immunohistochemical profiling cannot establish the primary tumor site. Here we present a patient diagnosed with both a malignant neop
Externí odkaz:
https://doaj.org/article/da0701258f32419591a4068c8d7137be
Autor:
Norma A. Palma, Siraj M. Ali, Jamie O'Connor, Deepa Dutta, Kai Wang, Salil Soman, Gary A. Palmer, Deborah Morosini, Jeffrey S. Ross, Doron Lipson, Phil J. Stephens, Mayur Patel, Vincent A. Miller, Nicholas Koutrelakos
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 2, Pp 503-508 (2014)
Background: Carcinoma of unknown primary (CUP) accounts for 3-5% of all adult solid tumors. An extensive search for the anatomic site of origin is often undertaken in an attempt to tailor systemic treatment, but the latter often has limited efficacy
Externí odkaz:
https://doaj.org/article/c3e9468f60934015a6cc8287ab076e87
Autor:
Siraj M. Ali, Je He, Wade Carson, Phil J. Stephens, Joseph Fiorillo, Doron Lipson, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Jeffrey Sharman
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 2, Pp 343-348 (2014)
Context: For patients with metastatic papillary thyroid carcinoma (PTC) refractory to radioactive iodine (RAI) treatment, systemic chemotherapy has limited efficacy. Such tumors frequently harbor BRAF V600E, and this alteration may predict responsive
Externí odkaz:
https://doaj.org/article/068b19060d6f45fe85af7a3c1eb32353
Autor:
Paul J. Arciero, Stephen J. Ives, Alex E. Mohr, Nathaniel Robinson, Daniela Escudero, Jake Robinson, Kayla Rose, Olivia Minicucci, Gabriel O’Brien, Kathryn Curran, Vincent J. Miller, Feng He, Chelsea Norton, Maia Paul, Caitlin Sheridan, Sheriden Beard, Jessica Centore, Monique Dudar, Katy Ehnstrom, Dakembay Hoyte, Heather Mak, Aaliyah Yarde
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
The ideal exercise time of day (ETOD) remains elusive regarding simultaneous effects on health and performance outcomes, especially in women.Purpose: Given known sex differences in response to exercise training, this study quantified health and perfo
Externí odkaz:
https://doaj.org/article/118298d3ce1f4617975f15f09f7cc9ae
Autor:
Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming Wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Weng Jie, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Changan Sun, Hongying Wei, Chuan Li, Siraj M. Ali, Vincent A. Miller, Qiong Wu
Publikováno v:
Journal of Clinical Oncology. 40:3162-3171
PURPOSE Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compa